stockrow
Friday 6 November 2026
Export BCRX’s income statement to Excel — free account
BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
7.44
0.19
−2.49%
Follow BCRX
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 6.24 |
+8 more quarters Free account |
P/S ratio |
2.21 | 2.71 | 2.60 | 1.87 | |
P/FCF ratio |
5.81 | 6.81 | 7.42 | 4.74 | |
P/Operating CF |
64.56 | 24.39 | (37.32) | 5.61 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.72 | 3.22 | 3.30 | 2.11 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 5.45 | |
EV/Operating CF |
7.12 | 8.06 | 9.35 | 5.31 | |
EV/FCF |
7.14 | 8.11 | 9.41 | 5.34 | |
Quick Ratio |
0.62 | 2.22 | 1.78 | 1.95 | |
Current Ratio |
2.71 | 2.32 | 1.91 | 2.06 | |
Net Debt/EBITDA |
— | 4.92 | (0.89) | 0.79 | |
Debt/Assets |
0.00% | 150.47% | 184.94% | 93.53% | |
Debt/Equity |
0.00 | (1.85) | (1.55) | (4.04) | |
Asset Turnover |
1.85 | 1.85 | 1.87 | 1.74 | |
Operating CF/Net income |
0.87 | 1.33 | 0.09 | 1.19 | |
Capex/Depreciation |
0.00 | (0.70) | (0.28) | 0.36 | |
Interest Coverage |
2.52 | 4.54 | (35.47) | 18.42 | |
Research and Development Expense of Revenue |
32.29% | 23.81% | 38.56% | 10.05% | |
Selling, General and Administrative Expense of Revenue |
37.26% | 29.31% | 60.45% | 23.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.90% | 6.73% | 10.25% | 5.85% | |
Graham Net Nets |
(0.21) | (0.21) | (0.28) | (0.14) | |
Graham Number |
6.87 | 7.61 | 9.43 | 0.00 | |
Earnings Yield |
(16.21%) | (14.40%) | (18.17%) | 16.03% | |
Free Cash Flow Yield |
17.21% | 14.69% | 13.48% | 21.10% | |
Revenue per Share |
0.71 | 0.86 | 0.65 | 1.94 | |
Operating CF per Share |
0.13 | 0.41 | (0.26) | 1.39 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.13 | 0.41 | (0.26) | 1.39 | |
Cash per Share |
0.00 | 1.39 | 0.99 | 1.31 | |
Shareholders Equity per Share |
(1.55) | (1.79) | (2.29) | (0.57) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.55) | (1.79) | (2.29) | (0.57) | |
Free Cash Flow |
32.75 | 104.13 | (62.19) | 291.71 | |
Working Capital |
335.32 | 275.84 | 178.23 | 208.28 | |
Capital Expenditures |
(0.23) | (0.21) | (0.40) | (0.25) | |
Net Current Asset Value |
(457.30) | (527.46) | (645.27) | (228.96) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 5.41 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 4.80 | |
| Other line items | |||||
Average Receivables |
106.56 | 100.97 | 101.33 | 92.94 | |
Average Payables |
10.07 | 10.02 | 10.50 | 13.74 | |
Average Inventory |
9.49 | 5.55 | 6.43 | 6.74 | |
Average Assets |
518.75 | 507.52 | 472.55 | 502.29 | |
Average Common Equity |
(392.64) | (437.94) | (502.88) | (297.54) |
Columns are period end dates · fundamentals updated 4 Nov 2026